摘要
目的采用干预措施安全性系统综述报告规范PRISMA Harms清单,对中医药安全性系统综述的规范报告提供范例。方法通过计算机检索中国知网、万方数据、维普(VIP)三大中文数据库,提取中医药安全性系统综述的内容,并依据国际上已发表的PRISMA Harms清单对相应条目进行举例说明。结果共检索到211篇文献,最终纳入符合标准的文献116篇。根据中医药实例的筛选标准,选择出与PRISMA Harms清单报告条目的内容符合、描述较为准确、报告质量较好的文献共25篇,并从中给PRISMA Harms清单的每一个条目选取了1~2条范例。当范例存在明显局限时进行必要的补充说明。结论本研究通过检索文献列举了中医药安全性系统综述相应部分的实例,可为研究者撰写安全性系统综述提供参考,从而提高安全性系统综述的报告质量。所选取的部分实例报告质量距规范可能仍有差距,可随着最新文献的发表进行补充和替换。
Objective To provide examples for TCM safety systematic reviews based on PRISMA Harms checklist.Methods Three Chinese electronic databases (CNKI,WanFang and VIP) were searched from inception to October 2018.TCM safety systematic reviews were identified and extracted.Based on predefined criteria,reviews with contents that best meet the requirement of PRISMA Harms items were selected and provided as examples.One to two examples were provided for each item.Results 116 reviews were included and examples were selected from 25 papers,which were relatively consistent with the requirements of PRISMA Harms checklist items.Supplemental explanations were given when the examples had significant limitations.Conclusion Our study provided examples for the reporting of TCM safety systematic reviews according to PRISMA Harms.Examples were selected from published TCM systematic reviews,and may have limitations.An updated reporting examples will be considered with the publication of better quality systematic reviews.
作者
胡瑞学
文玲子
于明坤
任毅铭
曹卉娟
高佳琪
刘可心
赵璐明
李一琳
林子宜
张子萱
明扬
武雪岑
李迅
刘建平
费宇彤
HU Ruixue;WEN Lingzi;YU Mingkun;REN Yiming;CAO Huijuan;GAO Jiaqi;LIU Kexin;ZHAO Luming;LI Yilin;LIN Ziyi;ZHANG Zixuan;MING Yang;WU Xuecen;LI Xun;LIU Jianping;FEI Yutong(Centre for Evidence-Based Chinese Medicine,BUCM,Beijing 100029,China;Beijing University of Chinese Medicine,Beijing 102488,China)
出处
《中国药物警戒》
2019年第5期301-310,共10页
Chinese Journal of Pharmacovigilance
基金
国家自然科学基金(81830115):基于整体观和辨证论治复杂干预的中医疗效评价关键技术和结局指标研究
北京中医药大学教育课题(XJZX17005):科研产出型形成性评价方法在临床研究方法教学课程中的应用
中央高校基本科研业务费专项资金(2017-JYB-JS-149):急性下呼吸道感染治疗中中药及抗生素使用情况的处方分析及调查研究
